Eylea Market Analysis - Global Forecast to 2030

GURUGRAM, India - Aug. 26, 2025 - PRLog -- The global Eylea market was valued at USD 9,714 Million in 2024, and is predicted to reach USD 14,545 Million by 2030. Eylea, also known as aflibercept, is a medication primarily used for the treatment of several eye disorders including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), diabetic retinopathy (DR), and macular edema following retinal vein occlusion (RVO). Eylea helps improve vision and reduce the risk of blindness in patients suffering from these retinal diseases. Since its regulatory approval over a decade ago, Eylea has redefined standards for retinal disease management by offering a potent anti-VEGF therapy with a consistent safety profile. Backed by robust clinical evidence, it has earned trust among ophthalmologists and patients alike, driving widespread adoption across key indications.

The growing aging population worldwide is expected to propel the growth of the Eylea market over the forecast period. With age-related eye conditions such as macular degeneration and diabetic retinopathy rising among older adults, demand for effective treatments such as Eylea is expected to grow. Furthermore, the major companies in the Eylea market are focusing on new product launches to expand the range of treatment options and meet the evolving needs of patients.

For more details, please visit: https://apeloconsulting.com/product/global-eylea-market-b...